ENO2 and metastatic prostate carcinoma: It is more difficult to be diagnosed than t-NEPC since the latter always has a prior novel hormonal therapy for metastatic prostate cancer and an elevating level of neuroendocrine (NE) markers, such as neuron-specific enolase (NSE).